OXIS International, Inc. (OTCMKTS:OXIS)’s subsidiary Oxis Biotech, Inc. announced that Cassian Yee, M.D., joined company’s scientific advisory board. Dr. Yee is a Professor at Department of Immunology, and also at Department of Melanoma Medical Oncology.
OXIS International subsidiary disclosed that Dr. Yee was Professor at Division of Oncology and a Member in the Department of Immunology. He attained his medical degree from the very popular University of Manitoba based in Canada. He started with research fellowship at the Ontario Cancer Institute based in Toronto and then opted for medical residency at Stanford University.
OXIS International subsidiary further revealed that Dr. Yee concluded his and postdoctoral research studies and fellowship in medical oncology at the Fred Hutchinson Cancer Research Center and the University of Washington. He was awarded the prestigious Investigator Award from Cancer Research Institute, as well as Clinical Investigator award from the Damon Runyon Walter Winchell.
Few months ago, OXIS International disclosed that it intends to up-list the stock on NASDAQ platform. Investors considered the announcement as a reason to start buying, and eventually it pushed the stock price all the way to a new 52-week high of $0.07. Sadly, the hype was short-lived and the stock price soon found declining towards $0.03. It consolidated during the next few weeks but now, people seem to be interested in buying stock once again.
There is no press release of NASDAQ listing around and the company is not even the fastest moving OTC stock. Still, it has been recording consecutive green sessions since the beginning of May. As per the last annual report, the company had cash of $855,000 and current assets of $882,000.
In last trading session, the stock price of OXIS surged more than 2% to close the trading session at $0.0330. The gain came at a share volume of 3.50 million compared to average share volume of 4.93 million.